Benzinga
Benzinga
Benzinga
miércoles, septiembre 30

Sarepta Therapeutics Inc

SRPTNASDAQ
Trade with Public
Trade with Public
$18.33
-0.31-1.66%
Últ. Act.: Sep 30, 3:04 PM
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Sarepta Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Sarepta Therapeutics (SRPT).

Price Target Range — 6 Quarters

Analyst Consensus — 24 Analysts

9Buy
10Hold
5Sell
Consensus RatingOutperform# Analysts24Avg. Consensus PT$25Upside to Avg. PT+35.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →
DateFirmAnalystActionRating ChangePrice Target
Sep 30, 2026JP MorganAnupam RamaPT CutNeutral$23→$20
Sep 28, 2026NeedhamGil BlumMaintainedUnderperform—
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
JP Morgan Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20

JP Morgan analyst Anupam Rama maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and lowers the price target from $23 to $20.
Benzinga Newsdesk

PRO
Needham Reiterates Underperform on Sarepta Therapeuticsto Underperform

Needham analyst Gil Blum reiterates Sarepta Therapeutics (NASDAQ:SRPT) from Underperform to Underperform.
Benzinga Newsdesk

PRO
Piper Sandler Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20

Piper Sandler analyst Biren Amin maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and lowers the price target from $23 to $20.
Benzinga Newsdesk

PRO
Wolfe Research Upgrades Sarepta Therapeutics to Outperform, Announces $27 Price Target

Wolfe Research analyst Andy Chen upgrades Sarepta Therapeutics (NASDAQ:SRPT) from Peer Perform to Outperform and announces $27 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $5 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and maintains $5 price target.
Benzinga Newsdesk

PRO
Citigroup Maintains Sell on Sarepta Therapeutics, Raises Price Target to $13

Citigroup analyst Yigal Nochomovitz maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and raises the price target from $9 to $13.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved